HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Methoxsalen (Oxsoralen)

Subscribe to New Research on Methoxsalen

A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.

Also Known As:

Oxsoralen; 8 MOP; Xanthotoxin; 8-MOP; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Deltasoralen; Dermatech Brand of Methoxsalen; Dermox; Galderma Brand of Methoxsalen; Geroxalen; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; Meladinina; Meladinine; Meloxine; Methoxa-Dome; Mex-America Brand of Methoxsalen; Méladinine; Oxsoralen-Ultra; Puvalen; Sanofi-Synthelabo Brand of Methoxsalen; Ultramop; 8 Methoxypsoralen; 8MOP; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Mex America Brand of Methoxsalen; Oxsoralen Ultra; Sanofi Synthelabo Brand of Methoxsalen; 8-Methoxypsoralen; Ammoidin; 7H-Furo(3,2-g)(1)benzopyran-7-one, 9-methoxy-

Networked: 724 relevant articles (59 outcomes, 72 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60

Experts

1.	Saoo, Kousuke: 6 articles (07/2009 - 11/2003)
2.	Imaida, Katsumi: 6 articles (07/2009 - 11/2003)
3.	Yokohira, Masanao: 6 articles (07/2009 - 11/2003)
4.	Kamataki, Tetsuya: 5 articles (07/2009 - 11/2003)
5.	Takeuchi, Hijiri: 5 articles (07/2009 - 11/2003)
6.	Wolf, P: 4 articles (09/2011 - 10/2000)
7.	Hofer, A: 4 articles (09/2011 - 10/2000)
8.	Yamakawa, Keiko: 4 articles (07/2009 - 03/2006)
9.	Matsuda, Yoko: 4 articles (07/2009 - 03/2006)
10.	Marzano, Cristina: 4 articles (11/2005 - 09/2002)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 09/01/2011 - "Treatment responses were analysed in terms of Psoriasis Area and Severity Index (PASI) improvement, including complete remission (CR) and reduction of PASI by at least 90% (PASI 90) or 75% (PASI 75), at treatment completion for PUVA (median time 10·3 and 9·2 weeks, for 8-MOP and 5-MOP, respectively) and at week 12 for biologics. " 09/01/1979 - "Prior testing with this light source and topically applied methoxsalen achieved excellent results in psoriasis. " 10/01/2006 - "Our data indicate that in bath-PUVA treatment the use of a high (5 mg/L) methoxsalen concentration is substantially more effective in clearing chronic plaque-type psoriasis than a low (1 mg/L) concentration." 09/01/1980 - "A combination of methoxsalen and high-intensity ultraviolet A radiation was employed and its therapeutic efficacy in nail psoriasis ascertained. " 11/01/1977 - "Oral methoxsalen when used in the higher dose followed by sun exposure is an effective treatment for psoriasis. "
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/01/1991 - "Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL). " 09/01/2001 - "Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells." 07/01/1989 - "Methoxsalen and extracorporeal photoactivation in the treatment of cutaneous T-cell lymphoma." 02/01/2000 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing agent 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in treatment of selected T-cell mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. " 11/01/1998 - "Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell-mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. "
3.	Skin Diseases 04/01/2005 - "The results of the study indicate that at least 18 courses of local PUVA within 6 weeks, with a cumulative dose of 87 J/cm(2), are required to induce a significant decrease in the disease severity and an improvement in the infiltration of plaques due to 8-MOP gel at a concentration of 0.01% when treating chronic recurrent palmoplantar dermatoses." 01/01/1989 - "The administration of 8 - methoxypsoralen combined with UV-A exposure (PUVA) was found to be effective in a case of progressive pigmented purpuric dermatosis (PPPD). " 04/01/2005 - "Aims In this study, the efficacy of topical PUVA treatment with 8-methoxypsoralen (8-MOP) gel was compared with placebo plus UVA in chronic recurrent palmoplantar dermatoses. " 08/01/2015 - "8-Methoxypsoralen (8-MOP) is a well established drug in the treatment of various skin diseases. " 12/01/2012 - "The bifunctional compound furocumarin 8-methoxypsoralen (8-MOP) is widely used in the treatment of various inflammatory skin diseases. "
4.	Mycosis Fungoides 11/01/2015 - "Photochemochemotherapy with 8-methoxypsoralen and UV-A light (PUVA) is a well-established treatment for mycosis fungoides (MF), although evidence for this therapy by means of prospective studies is scarce. " 01/01/2005 - "We retrospectively evaluated the outcomes of bath-water delivery of 8-MOP (1 mg l(-1)) in 16 patients with early stage mycosis fungoides. " 01/01/1979 - "Nine patients with stages 2 or 3 mycosis fungoides (MF) and one with Sézary's syndrome were treated with oral methoxsalen and long-wave ultraviolet light. " 11/12/1977 - "Six patients with mycosis fungoides were treated with methoxsalen and long-wave ultraviolet light. " 08/01/1976 - "The cutaneous manifestations of mycosis fungoides have been successfully treated in nine patients for 16 to 28 months with oral methoxsalen and subsequent irradiation with longwave ultraviolet light. "
5.	Erythema 02/01/2012 - "This study determined the threshold doses for 'solar erythema' and for phototoxic responses to 8-methoxypsoralen (8-MOP) in white skin Hanford and grey skin Yucatan miniature swine. " 03/01/2003 - "Methoxsalen-UV-A erythema exhibited a broad plateau between 96 and 144 hours, with most subjects at peak erythema at 120 hours. " 03/01/2003 - "The PUVA erythema after 15-minute methoxsalen immersion exhibited a broad peak, with the lowest median minimal phototoxic dose (MPD) at 96, 120, and 144 hours after UV-A irradiation. " 03/01/2003 - "The characteristics of PUVA erythema following 15- and 5-minute immersion in methoxsalen was determined. " 03/01/2003 - "The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion."

Related Drugs and Biologics

1.	Methoxsalen (Oxsoralen)
2.	Ficusin (Psoralen)
3.	5-methoxypsoralen (bergapten)
4.	DNA (Deoxyribonucleic Acid)
5.	Psoralens
6.	Anthralin (Dithranol)
7.	Polymethyl Methacrylate (Sol)
8.	Retinoids
9.	4-Aminobenzoic Acid (4 Aminobenzoic Acid)
10.	Etretinate

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Phototherapy (Light Therapy)
3.	PUVA Therapy
4.	Organ Transplantation
5.	Photopheresis